The Possible Effects of Ursodeoxycholic Acid on Recurrent Primary Biliary Cholangitis and Biliary Complications After Liver Transplant.
作者信息
Pedersen Mark
机构信息
Division of Digestive and Liver Disease UT Southwestern Medical Center Dallas, Texas.
出版信息
Gastroenterol Hepatol (N Y). 2021 Sep;17(9):439-442.
Abstract
摘要
相似文献
1
The Possible Effects of Ursodeoxycholic Acid on Recurrent Primary Biliary Cholangitis and Biliary Complications After Liver Transplant.
Gastroenterol Hepatol (N Y). 2021 Sep;17(9):439-442.
2
Cost effectiveness of using ursodeoxycholic acid to treat primary biliary cholangitis.
Br J Hosp Med (Lond). 2018 Aug 2;79(8):460-464. doi: 10.12968/hmed.2018.79.8.460.
3
Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid.
Curr Gastroenterol Rep. 1999 Feb-Mar;1(1):38-41. doi: 10.1007/s11894-999-0085-4.
4
Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
J Hepatol. 2019 Aug;71(2):357-365. doi: 10.1016/j.jhep.2019.04.001. Epub 2019 Apr 11.
5
Current Status of Liver Transplantation for Primary Biliary Cholangitis.
Clin Liver Dis. 2018 Aug;22(3):613-624. doi: 10.1016/j.cld.2018.03.011.
6
Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)?
Aliment Pharmacol Ther. 2003 Jan;17(1):17-27. doi: 10.1046/j.1365-2036.2003.01381.x.
7
Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis.
J Hepatol. 1998 Sep;29(3):409-16. doi: 10.1016/s0168-8278(98)80058-5.
8
Survival without biliary complications after liver transplant for primary sclerosing cholangitis.
Exp Clin Transplant. 2013 Dec;11(6):510-21. doi: 10.6002/ect.2013.0051.
9
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
N Engl J Med. 2018 Jun 7;378(23):2171-2181. doi: 10.1056/NEJMoa1714519.
10
[Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Tidsskr Nor Laegeforen. 1997 Sep 30;117(23):3370-3.
本文引用的文献
1
Ursodeoxycholic Acid Decreases Incidence of Primary Biliary Cholangitis and Biliary Complications After Liver Transplantation: A Meta-Analysis.
Liver Transpl. 2021 Jun;27(6):866-875. doi: 10.1002/lt.25935.
2
UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice.
J Hepatol. 2020 Sep;73(3):499-501. doi: 10.1016/j.jhep.2020.04.040. Epub 2020 Jun 20.
3
Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.
J Hepatol. 2020 Sep;73(3):559-565. doi: 10.1016/j.jhep.2020.03.043. Epub 2020 Apr 7.
4
Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
Gut. 2020 Aug;69(8):1502-1509. doi: 10.1136/gutjnl-2019-319057. Epub 2019 Dec 16.
5
An impaired biliary bicarbonate umbrella may be involved in dysregulated autophagy in primary biliary cholangitis.
Lab Invest. 2018 Jun;98(6):745-754. doi: 10.1038/s41374-018-0045-4. Epub 2018 Mar 14.
6
Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study.
Hepatol Commun. 2017 May 16;1(5):394-405. doi: 10.1002/hep4.1037. eCollection 2017 Jul.
7
Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.
J Hepatol. 2015 Dec;63(6):1449-58. doi: 10.1016/j.jhep.2015.07.038. Epub 2015 Aug 14.
8
Risk factors and outcomes in post-liver transplantation bile duct stones and casts: A case-control study.
Liver Transpl. 2008 Oct;14(10):1461-5. doi: 10.1002/lt.21511.
9
Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Liver Transpl. 2007 Sep;13(9):1236-45. doi: 10.1002/lt.21124.
Zotero 插件